Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rani Therapeutics Holdings (RANI) Income from Non-Controlling Interests (2020 - 2026)

Rani Therapeutics Holdings' Income from Non-Controlling Interests history spans 7 years, with the latest figure at -$982000.0 for Q1 2026.

  • On a quarterly basis, Income from Non-Controlling Interests rose 82.06% to -$982000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was -$6.8 million, a 72.58% increase, with the full-year FY2025 number at -$11.3 million, up 57.55% from a year prior.
  • Income from Non-Controlling Interests came in at -$982000.0 for Q1 2026, down from $1.2 million in the prior quarter.
  • The five-year high for Income from Non-Controlling Interests was $1.2 million in Q4 2025, with the low at -$9.4 million in Q2 2023.
  • Historically, Income from Non-Controlling Interests has averaged -$6.2 million across 5 years, with a median of -$7.0 million in 2023.
  • Biggest five-year swings in Income from Non-Controlling Interests: tumbled 52.09% in 2022 and later skyrocketed 118.17% in 2025.
  • Year by year, Income from Non-Controlling Interests stood at -$8.6 million in 2022, then grew by 18.69% to -$7.0 million in 2023, then grew by 2.62% to -$6.8 million in 2024, then soared by 118.17% to $1.2 million in 2025, then tumbled by 179.77% to -$982000.0 in 2026.
  • Business Quant data shows Income from Non-Controlling Interests for RANI at -$982000.0 in Q1 2026, $1.2 million in Q4 2025, and -$2.5 million in Q3 2025.